Endoscopy

Glucagon-like peptide-1 receptor agonist use for obesity management continues to rise, but not without concerns for use during elective surgery – uncertainty remains over whether halting them beforehand is the safest option for patients.

A no-drain strategy after gastrectomy increased the risk for reoperation or percutaneous drain placement within 30 days compared with prophylactic drainage among patients with gastric cancer, according to a study published in JAMA Surgery.

Following backlash, Anthem Blue Cross Blue Shield stalled its policy change that would have put a time limit on coverage for anesthesiology services during surgery and other procedures in Connecticut, Missouri and New York.

PHILADELPHIA — A “high prevalence” of extremity repetitive use injury symptoms were reported among endoscopists, which negatively affected performance, according to a presenter at the ACG Annual Scientific Meeting.

PHILADELPHIA — Glucagon-like peptide-1 receptor agonist use was associated with prolonged gastric transit time and incomplete small bowel evaluation among patients with diabetes undergoing video capsule endoscopy, according to research.

PHILADELPHIA — Although glucagon-like peptide-1 receptor agonist use may increase the risk for retained gastric contents in those undergoing endoscopic procedures, a 24-hour clear liquid diet may be “protective” vs. holding the medication.

Use of glucagon-like peptide-1 receptor agonists was associated with an increased risk for gastric food retention during single endoscopic procedures, although this risk was low when combined with colonoscopy, according to research.

In a Healio video exclusive, members of the ACG Board of Governors voiced concerns over the potential impact of UnitedHealthcare’s national Gold Card program for gastrointestinal procedures following its launch on Oct. 1, 2024.

In a Healio video exclusive, Edward V. Loftus Jr., MD, noted that the booming popularity in glucagon-like peptide-1 agonists have spurred an interspecialty “dilemma” regarding aspiration risks in the endoscopy suite.

The use of glucagon-like peptide-1 receptor agonists exponentially increased in recent years for treating diabetes and obesity, with benefits also observed in other cardiometabolic syndromes.